Shire plc, the global specialty biopharmaceutical company, announces that it has settled all pending litigation with Sandoz, Inc. ("Sandoz") in connection with Sandoz's Abbreviated New Drug Application ("ANDA") and its attempt to market generic versions of Shire's ADDERALL XR(R) (mixed amphetamine salts) for the treatment of Attention Deficit Hyperactivity Disorder.

PHILADELPHIA - - Settlement Ends all Litigation With Generics Over ADDERALL XR(R) Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has settled all pending litigation with Sandoz, Inc. (”Sandoz”) in connection with Sandoz’s Abbreviated New Drug Application (”ANDA”) and its attempt to market generic versions of Shire’s ADDERALL XR(R) (mixed [...]

DUBLIN, August 5 /PRNewswire-FirstCall/ -- - 2009 Guidance Framework Reaffirmed Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to June 30, 2009. Q2 2009 Financial Highlights Q2 2009(1) Product sales $558 million -21% Product sales (excluding ADDERALL XR) $491 million +20% Prod

Shire plc , the global specialty biopharmaceutical company, announces that its Annual Report and Accounts in respect of the year ended December 31, 2008 has been published on its website.

PHILADELPHIA, Pennsylvania and DUBLIN, Ireland, February 19 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the year to December 31, 2008 - a year which has seen significant growth in Shire's new product portfolio.